June 04, 2011
Bone Drug Reduces Odds for Breast Cancer's Return:
StudyEarly stage breast cancer
patients can see their chances of the cancer's return drop by 32
percent when the osteoporosis drug Zometa is added to regular
hormone therapy for three years after surgery, Austrian researchers
report.